It is an isocitrate dehydrogenase-1 (IDH1) inhibitor drug indicated for the treatment of adult patients with relapsed or refractory acute myelogenous leukemia (AML) with a susceptible IDH1 mutation.

Manufacturer – AGIOS PHARMACEUTICALS
Specialty – Oncology / Hematology
Active principle – Ivosidenib